Literature DB >> 20632133

Visual dysfunction associated with diabetic retinopathy.

Gregory R Jackson1, Alistair J Barber.   

Abstract

Diabetic retinopathy is a leading cause of blindness and is commonly viewed as a vascular complication of diabetes mellitus. However, diabetes mellitus causes visual dysfunction before the onset of clinically visible microvascular changes associated with diabetic retinopathy. Thus, viewing diabetic retinopathy more generally as a neurovascular disease may lead to an improved understanding of the mechanisms responsible for vision loss. This article reviews the impact of diabetes mellitus on inner and outer retinal visual and electrophysiologic function and advocates for a multimodal approach to the study of diabetic retinopathy.

Entities:  

Mesh:

Year:  2010        PMID: 20632133     DOI: 10.1007/s11892-010-0132-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  43 in total

1.  Diabetic retinopathy.

Authors:  J R WOLTER
Journal:  Am J Ophthalmol       Date:  1961-05       Impact factor: 5.258

2.  A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors:  Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal:  Ophthalmology       Date:  2007-08-15       Impact factor: 12.079

3.  Macular recovery time recorded by nyctometry--a screening method for selection of patients who are at risk of developing proliferative diabetic retinopathy. Results of a 5-year follow-up.

Authors:  K Frost-Larsen; H W Larsen
Journal:  Acta Ophthalmol Suppl       Date:  1985

4.  Hyperoxia improves contrast sensitivity in early diabetic retinopathy.

Authors:  A Harris; O Arend; R P Danis; D Evans; S Wolf; B J Martin
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  Visual fields correlate better than visual acuity to severity of diabetic retinopathy.

Authors:  B Bengtsson; A Heijl; E Agardh
Journal:  Diabetologia       Date:  2005-11-01       Impact factor: 10.122

6.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

8.  Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy.

Authors:  Hille W van Dijk; Pauline H B Kok; Mona Garvin; Milan Sonka; J Hans Devries; Robert P J Michels; Mirjam E J van Velthoven; Reinier O Schlingemann; Frank D Verbraak; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

9.  Predicting progression to severe proliferative diabetic retinopathy.

Authors:  G H Bresnick; M Palta
Journal:  Arch Ophthalmol       Date:  1987-06

10.  Normative and clinical data with a new type of dark adaptometer.

Authors:  D B Henson; D E Williams
Journal:  Am J Optom Physiol Opt       Date:  1979-04
View more
  41 in total

Review 1.  Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms.

Authors:  C Hernández; A Simó-Servat; P Bogdanov; R Simó
Journal:  J Endocrinol Invest       Date:  2017-03-29       Impact factor: 4.256

Review 2.  Dopamine metabolite levels in the vitreous of diabetic and non-diabetic humans.

Authors:  Andrew Hendrick; Jesse Smith; Chris Stelton; Scott Barb; Jiong Yan; Blaine Cribbs; Nieraj Jain; Steve Yeh; G Baker Hubbard; Li He; Susov Dhakal; P Michael Iuvone
Journal:  Exp Eye Res       Date:  2020-04-29       Impact factor: 3.467

3.  Early neurodegeneration in the retina of type 2 diabetic patients.

Authors:  Hille W van Dijk; Frank D Verbraak; Pauline H B Kok; Marilette Stehouwer; Mona K Garvin; Milan Sonka; J Hans DeVries; Reinier O Schlingemann; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

Review 4.  Multifocal electroretinography in diabetic retinopathy and diabetic macular edema.

Authors:  Marcus A Bearse; Glen Y Ozawa
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

Review 5.  Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment.

Authors:  Steven F Abcouwer; Thomas W Gardner
Journal:  Ann N Y Acad Sci       Date:  2014-03-27       Impact factor: 5.691

6.  Reductions in Calcium Signaling Limit Inhibition to Diabetic Retinal Rod Bipolar Cells.

Authors:  Johnnie M Moore-Dotson; Erika D Eggers
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-09-03       Impact factor: 4.799

Review 7.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

Authors:  Elia J Duh; Jennifer K Sun; Alan W Stitt
Journal:  JCI Insight       Date:  2017-07-20

8.  Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes.

Authors:  Moe H Aung; Han Na Park; Moon K Han; Tracy S Obertone; Jane Abey; Fazila Aseem; Peter M Thule; P Michael Iuvone; Machelle T Pardue
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

9.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

10.  Insulin treatment normalizes retinal neuroinflammation but not markers of synapse loss in diabetic rats.

Authors:  Dustin R Masser; Heather D VanGuilder Starkey; Georgina V Bixler; Wendy Dunton; Sarah K Bronson; Willard M Freeman
Journal:  Exp Eye Res       Date:  2014-06-12       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.